ライフサイエンスコーパス: cytotoxic T-lymphocyte antigen 4

1 ses antitumor T-cell responses by binding to cytotoxic T-lymphocyte antigen 4.

2 T, insulin like growth factor 1 receptor and cytotoxic T-lymphocyte antigen 4.

3 ssibly by a mechanism involving IL-10 and/or cytotoxic T-lymphocyte antigen 4.

4 as blocking PD-L1 or PD-1, but not PD-L2 and cytotoxic T-lymphocyte antigen 4, abrogated long-term su

5 Although cytotoxic T lymphocyte antigen 4 and programmed death-1

6 Interestingly, the co-inhibitory molecules cytotoxic T lymphocyte antigen-4 and B and T lymphocyte

7 b is a human monoclonal antibody that blocks cytotoxic T-lymphocyte antigen 4 and has shown promising

8 more phenotypically exhausted with increased cytotoxic T-lymphocyte antigen 4 and reduced CD28 and CD

9 Neutralization of cytotoxic T-lymphocyte antigen 4 and transforming growth

10 CD28 costimulation but required CD8+ cells, cytotoxic T lymphocyte antigen-4, and an intact signal t

11 tic melanoma using a fully human antibody to cytotoxic T-lymphocyte antigen-4 (anti-CTLA-4) in conjun

12 anide ISA 51 and received a fully human anti-cytotoxic T-lymphocyte antigen-4 (anti-CTLA-4) monoclona

13 T-cell responses, blocking antibodies (anti-cytotoxic T-lymphocyte antigen 4, anti-programmed death

14 e been developed include ipilimumab, an anti-cytotoxic T lymphocyte antigen 4 antibody that enhances

15 via monoclonal antibodies, such as the anti-cytotoxic T-lymphocyte antigen-4 antibody (ipilimumab),

16 checkpoints (eg, programmed cell death 1 and cytotoxic T-lymphocyte antigen 4), are under investigati

17 ock inhibitory molecules on T cells, such as cytotoxic T lymphocyte antigen-4, are currently under st

18 -induced tumor necrosis factor receptor, and cytotoxic T lymphocyte antigen 4) associated with the T

19 rget antigens, has led to the development of cytotoxic T lymphocyte antigen-4-blocking antibodies as

20 bitor), alone or combined with ipilimumab (a cytotoxic T-lymphocyte antigen-4 checkpoint inhibitor),

21 e for eight polymorphic markers spanning the cytotoxic T lymphocyte antigen-4 ( CTLA-4 ) region of ch

22 Cytotoxic T lymphocyte antigen 4 (CTLA-4) and CD80 compr

23 fects of blockade of the interaction between cytotoxic T lymphocyte antigen 4 (CTLA-4) and its ligand

24 Considering that TIM-3, like cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed

25 ntibodies to block negative immune regulator cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed

26 It remains clear, however, that CD28 and cytotoxic T lymphocyte antigen 4 (CTLA-4) are the critic

27 We show that cytotoxic T lymphocyte antigen 4 (CTLA-4) engagement cou

28 Cytotoxic T lymphocyte antigen 4 (CTLA-4) engagement sel

29 Inducible costimulator (ICOS), a CD28/cytotoxic T lymphocyte antigen 4 (CTLA-4) family member,

30 advances in our understanding of the role of cytotoxic T lymphocyte antigen 4 (CTLA-4) in regulating

31 Cytotoxic T lymphocyte antigen 4 (CTLA-4) is an essentia

32 Ipilimumab, a monoclonal antibody against cytotoxic T lymphocyte antigen 4 (CTLA-4), has been show

33 ctivated T cells that is distinct from CD28, cytotoxic T lymphocyte antigen 4 (CTLA-4), inducible cos

34 action with CD28 and its alternative ligand, cytotoxic T lymphocyte antigen 4 (CTLA-4).

35 , which include a receptor on T cells termed cytotoxic T lymphocyte antigen 4 (CTLA-4).

36 s that constitutively express high levels of cytotoxic T lymphocyte antigen-4 (CTLA-4) and suppress T

37 Cytotoxic T lymphocyte antigen-4 (CTLA-4) blockade with

38 Mice lacking the co-inhibitory receptor cytotoxic T lymphocyte antigen-4 (CTLA-4) develop fatal

39 ers of regulatory T cells (Tregs), increased cytotoxic T lymphocyte antigen-4 (CTLA-4) expression, an

40 Cytotoxic T lymphocyte antigen-4 (CTLA-4) is a regulator

41 Cytotoxic T lymphocyte antigen-4 (CTLA-4) is an essentia

42 The protein cytotoxic T lymphocyte antigen-4 (CTLA-4) is an essentia

43 Cytotoxic T lymphocyte antigen-4 (CTLA-4) is an inhibito

44 Cytotoxic T lymphocyte antigen-4 (CTLA-4) is an inhibito

45 While cytotoxic T lymphocyte antigen-4 (CTLA-4) negatively reg

46 ties in the phenotypes of mice deficient for cytotoxic T lymphocyte antigen-4 (CTLA-4) or transformin

47 Cytotoxic T lymphocyte antigen-4 (CTLA-4) plays a critic

48 We examined how cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates hete

49 We and others previously reported that cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates the

50 CD28 and its homologue cytotoxic T lymphocyte antigen-4 (CTLA-4) share the same

51 he contribution of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 (CTLA-4) to CD8 T cell

52 Cross-linking of ligand-engaged cytotoxic T lymphocyte antigen-4 (CTLA-4) to the T cell

53 oimmunity by increasing surface retention of cytotoxic T lymphocyte antigen-4 (CTLA-4) via interactio

54 also induced by MAb blockade (inhibition) of cytotoxic T lymphocyte antigen-4 (CTLA-4) which downregu

55 ression of CD3 and the TCR, up-regulation of cytotoxic T lymphocyte antigen-4 (CTLA-4), and calcium m

56 Thus, cytotoxic T lymphocyte antigen-4 (CTLA-4), programmed de

57 The cytotoxic T lymphocyte antigen-4 (CTLA-4)-blocking antib

58 co-stimulation blockade-based regimen using cytotoxic T lymphocyte antigen-4 (CTLA-4)-Ig, a CD80- an

59 dendritic cells (DCs) by recombinant soluble cytotoxic T lymphocyte antigen-4 (CTLA-4-Fc).

60 nt of immune checkpoint inhibitors targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed

61 dels have proven the concept for use of anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) antibodies in

62 on T-cell activation, whereas engagement of cytotoxic T-lymphocyte antigen 4 (CTLA-4) by these molec

63 forkhead box P3 (FOXP3), and the inhibitory cytotoxic T-lymphocyte antigen 4 (CTLA-4) coreceptor.

64 and/or Mgat5 prevents T cell hyperactivity, cytotoxic T-lymphocyte antigen 4 (CTLA-4) endocytosis, s

65 ssion of programmed death 1 (PD-1) and lower cytotoxic T-lymphocyte antigen 4 (CTLA-4) expression tha

66 Cytotoxic T-lymphocyte antigen 4 (CTLA-4) is an inhibito

67 CD28 and its homologue, cytotoxic T-lymphocyte antigen 4 (CTLA-4), are the prima

68 or ovalbumin in vivo or in vitro, and CD28, cytotoxic T-lymphocyte antigen 4 (CTLA-4), CD69, and pho

69 umab and tremelimumab are antibodies against cytotoxic T-lymphocyte antigen 4 (CTLA-4).

70 f key Treg genes, such as interleukin-10 and cytotoxic T-lymphocyte antigen 4 (CTLA-4).

71 ed in a murine tumor xenograft model of anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) immunotherapy

72 The gene encoding cytotoxic T-lymphocyte antigen-4 (CTLA-4) on chromosome

73 ssion of the negative costimulatory molecule cytotoxic T-lymphocyte antigen-4 (CTLA-4) on T cells mod

74 f the negative T-cell costimulatory receptor cytotoxic T-lymphocyte antigen-4 (CTLA-4) promotes rejec

75 tment with recombinant Wnt-3a and found that cytotoxic T-lymphocyte antigen-4 (CTLA-4) was the most h

76 dies (ipilimumab and tremelimumab) targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4), an inhibitory

77 cytokine secretion without binding to CD28, cytotoxic T-lymphocyte antigen-4 (CTLA-4), and inducible

78 nd SNP descriptor) were studied in subjects: cytotoxic T-lymphocyte antigen-4 (CTLA-4, 49 A>G), human

79 rected against the immune checkpoint protein cytotoxic T-lymphocyte antigen-4 (CTLA-4; CD152)-ipilimu

80 kers for differentiation (CD127) and anergy (cytotoxic T lymphocyte antigen 4 [CTLA-4] and programmed

81 pression (programmed cell death 1 [PD-1] and cytotoxic T-lymphocyte antigen 4 [CTLA-4]) was similar t

82 Ligation of cytotoxic T lymphocyte antigen 4 (CTLA4) appears to inhi

83 Cytotoxic T lymphocyte antigen 4 (CTLA4) appears to nega

84 ulating T cell immune responses via CD28 and cytotoxic T lymphocyte antigen 4 (CTLA4) on T cells.

85 death ligand-1 (PD-1/PD-L1), but not through cytotoxic T lymphocyte antigen 4 (CTLA4), was shown to b

86 ory molecule blockade of CD28 is superior to cytotoxic T lymphocyte antigen 4 (CTLA4)-Ig.

87 We evaluated Eomes and coinhibitory cytotoxic T lymphocyte antigen-4 (CTLA4) expression by a

88 New immune checkpoint inhibitors blocking cytotoxic T lymphocyte antigen-4 (CTLA4) or programmed d

89 Cytotoxic T lymphocyte antigen-4 (CTLA4) suppresses cyto

90 Cytotoxic T-lymphocyte antigen 4 (CTLA4) and programmed

91 Cytotoxic T-lymphocyte antigen 4 (CTLA4) encodes a coinh

92 Cytotoxic T-lymphocyte antigen 4 (CTLA4) has been shown

93 rphism (rs231725) of the immunoreceptor gene cytotoxic T-lymphocyte antigen 4 (CTLA4).

94 ween HLA class II genotypes and rs3087243 at cytotoxic T-lymphocyte antigen 4 (CTLA4)/2q33.2 was obta

95 d CD25, CD62L, CCR7, CD27, and intracellular cytotoxic T-lymphocyte antigen-4 (CTLA4).

96 lyses were done to assess the association of cytotoxic T-lymphocyte-antigen 4 (CTLA4) and protein tyr

97 defensin, beta 4A [DEFB4A]) or dermal (IL22, cytotoxic T-lymphocyte antigen 4 [CTLA4], and CCR7) and

98 ion of soluble recombinant fusion protein of cytotoxic T lymphocyte antigen 4 (CTLA4Ig) induces block

99 The dNP2-conjugated cytoplasmic domain of cytotoxic T-lymphocyte antigen 4 (dNP2-ctCTLA-4) negativ

100 latory blockade by in vivo administration of Cytotoxic T-Lymphocyte Antigen 4 fusion protein (CTLA4-I

101 Here we identify polymorphisms of the cytotoxic T lymphocyte antigen 4 gene (CTLA4)--which enc

102 Polymorphisms of the cytotoxic T lymphocyte antigen-4 gene may synergize with

103 Cytotoxic T lymphocyte antigen-4 has become recognized a

104 a human monoclonal antibody targeted against cytotoxic T-lymphocyte antigen 4, has shown promise in t

105 of metastatic urothelial carcinoma, tubulin, cytotoxic T-lymphocyte antigen 4, Hsp27, and p53 are nov

106 ectin antagonist; and (ii) a fusion protein, cytotoxic T lymphocyte antigen 4-Ig, which blocks B7-med

107 s combined with suboptimal concentrations of cytotoxic T-lymphocyte antigen 4-Ig or cyclosporine.

108 r does FE depend on Fas, TNF-alpha receptor, cytotoxic T-lymphocyte antigen-4, IL-2, or IFN-gamma.

109 Anti-CD154 mAb and cytotoxic T-lymphocyte antigen 4 immunoglobulin were ine

110 ach of monoclonal antibody against CD154 and cytotoxic T-lymphocyte antigen 4 immunoglobulin, resulte

111 ver, when combined with a suboptimal dose of cytotoxic T-lymphocyte antigen-4 immunoglobulin (200 mic

112 when administered with a suboptimal dose of cytotoxic T-lymphocyte antigen-4 immunoglobulin or cyclo

113 provement in response to abatacept, a CTLA4 (cytotoxic T lymphocyte antigen-4)-immunoglobulin fusion

114 liferation triggered by DCs was abrogated by cytotoxic T lymphocyte antigen 4-immunoglobulin (CTLA-4-

115 It appeared that the addition of cytotoxic T lymphocyte antigen 4-immunoglobulin fusion p

116 Survivals of cytotoxic T lymphocyte antigen 4-immunoglobulin fusion p

117 cell costimulatory signal from B7-->CD28 by cytotoxic T lymphocyte antigen 4-immunoglobulin fusion p

118 dies reactive against CD80 or by recombinant cytotoxic T-lymphocyte antigen 4-immunoglobulin fusion p

119 from FL-treated B10 (H2b) donors were given cytotoxic T-lymphocyte antigen 4: immunoglobulin (CTLA4I

120 -induced tumor necrosis factor receptor, and cytotoxic T lymphocyte antigen 4 increased significantly

121 rejection, whereas ipilimumab (anti-CTLA-4 [cytotoxic T-lymphocyte antigen-4] mAb) treatment acceler

122 lines how the coinhibitory receptors CTLA-4 (cytotoxic T-lymphocyte antigen-4), PD-1 (programed death

123 The three coinhibitory receptors are cytotoxic T lymphocyte antigen 4, programmed death-1, an

124 and overexpression of regulatory molecules (cytotoxic T-lymphocyte antigen 4, programmed cell death

125 A similar motif in cytotoxic T-lymphocyte antigen-4 recruits the related ty

126 engraftment remains absolutely dependent on cytotoxic T lymphocyte antigen 4 signaling, even after g

127 fts contained high levels of mRNA for foxp3, cytotoxic T lymphocyte antigen-4, TGF-beta, IL-10, and I

128 nd 1 expression, BRAF status, and best prior cytotoxic T-lymphocyte antigen-4 therapy response, then

129 a fully human monoclonal antibody that binds cytotoxic T-lymphocyte antigen 4 to enhance antitumour i